I'm looking for

All Events

Annual Meeting Industry Supported Symposia

ISS at THE SGO 2024 Annual Meeting

Industry Supported Symposia (ISS) are unique forums for presenting educational information to SGO 2024 Annual Meeting on Women’s Cancer attendees, free of charge. View a listing of the ISS sessions below including registration links where applicable.

All 2024 ISS events are in-person attendance and breakfast or lunch will be provided. Onsite registration and meals will begin thirty minutes prior to the start of each ISS.

SGO does not offer CE for any of the ISS. The offering of ISS does not constitute endorsement by the SGO of the information, products or services contained therein. SGO will not share content or video from any ISS session. 

Advertisement

Advertise With Us

ISS I: Maintenance Therapy in Advanced Ovarian Cancer: Results from Key Clinical Trials

Supporting Company: AstraZeneca

Date: Saturday, March 16, 2024

Time: 12:15 p.m. – 1:45 p.m.

Location: Ballroom 20 AB

Faculty: John K. Chan, MD, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center

Description:

  • Describe the need for first-line maintenance of advanced ovarian cancer following response to first-line chemotherapy
  • Discuss the data from PAOLA-1 demonstrating the efficacy and safety of LYNPARZA in combination with bevacizumab as first-line maintenance treatment for HRD-positive advanced ovarian cancer
  • Highlight the data from SOLO-1 supporting LYNPARZA first-line maintenance therapy as the standard of care in BRCAm advanced ovarian cancer
  • Understand the safety and tolerability profile of LYNPARZA across pivotal trials

Registration not required 

 

ISS II: A Treatment Option for Patients with Primary Advanced or Recurrent dMMR/MSI-H Endometrial Cancer

Supporting Company: GSK

Date: Saturday, March 16, 2024

Time: 12:15 p.m. – 1:45 p.m.

Location: Ballroom 20 CD

Faculty:

  • Dana Chase, MD, FACOG, Associate Professor, David Geffen School of Medicine at University of California, Los Angeles

Description:

  • Review the incidence of endometrial cancer (EC) and the importance of biomarker testing
  • Learn about the efficacy and safety data of JEMPERLI in combination with carboplatin and paclitaxel for primary advanced or recurrent dMMR/MSI-H EC from the RUBY trial
  • Review the Important Safety Information for JEMPERLI

Registration not required 

 

ISS III: Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Practical Tips for Patient Care

Supporting Company: This symposium is presented by PeerView Institute for Medical Education (PVI) and supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., ImmunoGen, Inc., Seagen and Genmab

Date: Sunday, March 17, 2024

Time: 7:00 a.m. – 8:30 a.m.

Location: Ballroom 28 ABCDE

Faculty:

  • Chair: Bradley J. Monk, MD, FACS, FACOG, Florida Cancer Specialists and Research Institute
  • Presenter: Kathleen N. Moore, MD, MS, Stephenson Cancer Center at the University of Oklahoma Health Sciences Center
  • Presenter: Ana Oaknin, MD, PhD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Description: In a new Clinical Consults event developed by PeerView Live in collaboration with the National Ovarian Cancer Coalition and the Foundation for Women’s Cancer, a panel of experts combines foundational knowledge on the science supporting the use of ADCs in the treatment of gynecologic malignancies with discussion of patient cases drawn from their own practice to illustrate key decision points. Get insight on safety and efficacy evidence supporting approved and emerging ADCs and practical guidance on incorporating these agents into personalized treatment plans, including via clinical trial enrollment. Key topics include the role of biomarker testing in patient selection, team-based approaches for managing treatment-related adverse events, and educating patients to foster shared decision-making.

rEGISTER

 

ISS IV: The Evolution of Biomarkers in Gynecological Malignancies

Supporting Company: GSK

Date: Sunday, March 17, 2024

Time:  7:00 a.m. – 8:30 a.m.

Location: Ballroom 30 ABCDE

Faculty:

  • Ritu Salani, MD, MBA, Professor, Obstetrics & Gynecology and Division Director for Gynecologic Oncology, University of California, Los Angeles Health
  • Debra L. Richardson, MD, Associate Professor and Chief, Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
  • Matthew A. Powell, MD, Professor of Obstetrics and Gynecology, & Chief, Division of Gynecologic Oncology, Siteman Cancer Center, Washington University

Description: This presentation will review advancements in biomarker-driven management of ovarian and endometrial cancers, how this information guides treatment selection, and how the landscape is evolving for the care of patients with gynecological malignancies.

Registration not required 

 

ISS V: A Treatment Option for Patients with A CERTAIN TYPE OF Advanced Cervical Cancer

Supporting Company: Merck

Date: Sunday, March 17, 2024

Time: 11:30 a.m. – 1:00 p.m.

Location: Ballroom 20 AB

Registration not required 

 

ISS VI: ADCs First to Cervix Cancer and Here to Stay: Understanding Provider and Patient Perspectives

Supporting Company: The GOG Foundation, Inc. in collaboration with Seagen, Inc. and Genmab

Date: Sunday, March 17, 2024

Time: 11:30 a.m. – 1:00 p.m.

Location: Ballroom 20 CD

Faculty:

  • Bhavana Pothuri, MD, MS, (Moderator) NYU Langone, Perlmutter Cancer Center, New York
  • Leslie M. Randall, MD, MAS, FACS, Virginia Commonwealth University
  • Susana Campos, MD, MPH, Dana Farber Cancer Institute
  • Kathleen Lutz, NP, New York University Langone, Perlmutter Cancer Center
  • Patient with recurrent cervix cancer

Description: The cervix cancer landscape is rapidly evolving with new data deriving from clinical trials. In this course, participants will learn about the current landscape treatment of recurrent cervix cancer. Physician experts will share the pivotal clinical trial and data insights from 2023 describing the changes to positively impact patients through new treatment options. The leadership for this course will also share the role of antibody drug conjugates in cervix cancer and describe ways to explain these new treatments to patients with recurrent disease. In addition to learning about new data and important advancements in the field of recurrent cervix cancer, the panel of experts will utilize case studies to help further explain how to best manage decision making when it comes to treatments. Finally, these experts will help the audience learn about the patient experience sharing important stories from the patient perspective.

rEGISTER

 

 

ISS VII: A Targeted Treatment for Ovarian Cancer

Supporting Company: Immunogen

Date: Monday, March 18, 2024

Time: 6:30 a.m. – 8:00 a.m.

Location: Ballroom 28 ABCDE

Faculty:

  • Leslie M. Randall, MD, MAS, FACS, Massey Cancer Center, Virginia Commonwealth University
  • Courtney Arn, APRN-CNP, Certified Women’s Health, Nurse Practitioner, The Ohio State University James Cancer Center

Description: Leslie M. Randall, MD, MAS, FACS, and Courtney Arn, APRN-CNP, will present on a targeted therapy in ovarian cancer, exploring clinical evidence and discussing patient care. The program will conclude with ImmunoGen Ocular Medical Director, Sarah Connolly, joining the expert panel to help answer frequently asked questions.

Registration not required 

 

ISS VIII: Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Ovarian Cancer

Part one of a two-part CME Symposium Series

Supporting Company: This activity is CME accredited by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, Merck, and Mural Oncology.

Date: Monday, March 18, 2024

Time: 6:30 a.m. – 8:00 a.m.

Location: Ballroom 30 ABCDE

Faculty:

  • Joyce F. Liu, MD, MPH, Dana-Farber Cancer Institute
  • Mansoor Raza Mirza, MD, Copenhagen University Hospital, Copenhagen, Denmark
  • David M. O’Malley, MD, The Ohio State University and The James Comprehensive Cancer Center
  • Moderator: Kathleen N. Moore, MD, MS, Stephenson Cancer Center at the University of Oklahoma Health Sciences Center

Description: This complimentary CME-accredited symposium, the first of a two-part series, will focus on the clinical management of ovarian cancer. Research To Practice will recruit a faculty panel of four clinical investigators, including a moderator, and two additional investigators, all of whom will answer approximately fifty controversial questions in a preparatory survey. A matrix displaying all six responses will be developed for each question, and the two consulting investigators will record video interviews in which they will discuss their answers. Select matrices and video excerpts will be shown at the beginning of each of the four symposium topic modules, followed by a panel discussion providing insight into any disparity in survey responses and a faculty presentation on relevant data sets and research. In-person and virtual attendees may submit questions for the faculty to address, and the activity will be webcast live.

Pre-registration is required. Onsite registration and meals will begin thirty minutes prior to the start of each ISS. 

rEGISTER

 

ISS IX: Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Endometrial Cancer

Part two of a two-part CME Symposium Series

Supporting Company: This activity is CME accredited by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Karyopharm Therapeutics.

Date: Monday, March 18, 2024

Time: 12:15 p.m. – 1:45 p.m.

Location: Ballroom 20 AB

Faculty:

  • Nicoletta Colombo, MD, PhD, University of Milan-Bicocca Milan, Italy
  • Matthew A. Powell, MD, Washington University School of Medicine
  • Brian M. Slomovitz, MD, Florida International University and Mount Sinai Medical Center
  • Moderator: Shannon N. Westin, MD, MPH, The University of Texas MD Anderson Cancer Center

Description:

This complimentary CME-accredited symposium, the second of a two-part series, will focus on the clinical management of endometrial cancer. Research To Practice will recruit a faculty panel of four clinical investigators, including a moderator, and two additional investigators, all of whom will answer approximately fifty controversial questions in a preparatory survey. A matrix displaying all six responses will be developed for each question, and the two consulting investigators will record video interviews in which they will discuss their answers. Select matrices and video excerpts will be shown at the beginning of each of the four symposium topic modules, followed by a panel discussion providing insight into any disparity in survey responses and a faculty presentation on relevant data sets and research. In-person and virtual attendees may submit questions for the faculty to address, and the activity will be webcast live.

Pre-registration is required. Onsite registration and meals will begin thirty minutes prior to the start of each ISS.

rEGISTER

 

ISS X: Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

Supporting Company: This symposium is presented by PeerView Institute for Medical Education (PVI) and supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.

Date: Monday, March 18, 2024

Time: 12:15 p.m. – 1:45 p.m.

Location: Ballroom 20 CD

Faculty:

  • Moderator: Kathleen N. Moore, MD, MS, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
  • Floor J. Backes, MD, The Ohio State University College of Medicine; The James Cancer Hospital and Solove Research Institute
  • Bhavana Pothuri, MD, MS, NYU Grossman School of Medicine, Laura and Isaac Perlmutter Cancer Center

Description: Which treatment advances are charting new standards of care for patients with endometrial or ovarian cancer? Use of immunotherapy-based approaches, ADCs, PARP inhibitors, and other innovative strategies have brought new hope for better outcomes in these gynecologic cancers, with many approvals and other strategies in late-stage development in a variety of settings. Join PeerView Live, the National Ovarian Cancer Coalition, and Foundation for Women’s Cancer for a live Clinical Consults event designed to bring participants the latest evidence on approved and emerging treatment strategies and practical guidance on incorporating effective treatments, including via clinical trial enrollment, into patient care. Learn where approved and emerging treatments fit into therapeutic algorithms for ovarian and endometrial cancer, how companion diagnostics guide individualized treatment selection, and best practices for collaborative, team-based management of treatment-related adverse events.

rEGISTER